However, clinical investigations have demonstrated that patients with IDH1 mutations experience significantly better clinical prognoses than those with wild-type gliomas (median overall survival: 3.8 years vs. 1.1 years) [7]. The gene discussed is IDH1; the disease is central nervous system cancer.